The genomics tool producer has raised more than $100m from investors including General Electric and Myriad Genetics.

Fosun Pharma-backed Check-Cap has received $12m in an initial public offering and an additional $12m in a private placement.

The Pfizer-backed cancer treatment developer, which initially floated in France in 2007, received $35m from Pfizer last year in return for a 10% stake.

Seagate-backed customised silicon device maker Easic aims to float on Nasdaq after raising $120m in venture funding.

The Israel-based solar inverter maker, which counts Norwest Venture Partners and GE Capital as backers, intends to float on Nasdaq.

MedImmune-backed Inotek, which is working on treatments for glaucoma, priced its IPO at $6a share and is set to secure an additional $20m in convertible debt.

Invitae, a genetic testing technology spin-out from Genomic Health, had initially raised $101.6m when it floated last week.

The agricultural biotechnology developer had raised $101m from investors including chemical producer BASF.

The Siemens-backed cancer treatment company, which has raised $195m in funding, will look to raise up to $69m when it floats on Nasdaq.

Poxel, which is also backed by Bpifrance, will fund clinical trials for two of its drug candidates with the proceeds.